Nutritional supplements and extracts like Feverfew have benefits and are used by cancer patients and those at-genetic risk of cancer. There is limited or hardly any clinical data available for use of nutritional supplements and foods in cancer patients. Generating clinical evidence of efficacy for cancer through a randomized clinical trial is further infeasible due to variations in genetics and cancer chemotherapy treatments across cancer patients. Hence a different and new approach is needed to find out for which cancers you should not take Feverfew supplement and why should not take them?
Is it okay to take Feverfew extracts or supplements for all cancer indications and any chemotherapy treatment? A common belief but a myth is that everything natural can only be of benefit and do no harm. For example, the use of grapefruit with certain medications is not recommended. Another example is the use of spinach with some blood thinning medications can cause adverse interactions and hence to be avoided. For cancer, nutrition including plant-based foods and supplements can influence outcomes and hence an extremely important decision which needs to be made. Hence NIH-National Cancer Institute has a website for nutrition for cancer care for patients which are generalized recommendations and not personalized for cancer indication and treatments.
A frequently asked question by cancer patients and those at-risk is “What Foods and Nutritional Supplements could be beneficial over others for me?”. “Who should not take an extract or supplement and why?”. Generic guidelines like eating only plant-based-foods or avoiding all sugar or adopting a keto diet is a good start but not actionable and personalized enough.
To find answers to questions on extracts and nutritional supplements and foods requires knowledge of contained active ingredients; genetic mutation prevalence for cancer indication; understanding of underlying cancer biology; chemotherapy treatments and mechanism of actions of active ingredients.
Taking Feverfew extracts or nutritional supplements may benefit Primary Monoclonal gammopathy of undetermined significance patients on Lenalidomide treatment over Lutein nutritional supplements. But Feverfew supplements or Feverfew extracts offer less benefit if on Pembrolizumab treatment for Primary Mucinous Stomach Adenocarcinoma compared to Dan Shen. Similarly, taking nutritional supplements Feverfew may benefit healthy individuals who are at genetic risk of cancer due to mutation of gene FLT3 over Coconut. But avoid nutritional supplements Feverfew when at genetic risk of cancer due to mutation of gene POLH.
The takeaway being – cancer, genomics, treatments and other personalized factors will influence decision making to questions like: Are extracts or nutritional supplements Feverfew beneficial and should not be taken? Why should Feverfew be not taken? Who should not take Feverfew? What are side effects of Feverfew with Pembrolizumab chemotherapy? What are the benefits of Feverfew for cancer? Can Feverfew help fight cancer and so on.
Whenever there are changes in chemotherapy treatments or cancer tissue genetics – the nutrition may change and hence needs to be re-evaluated. Do consider factors like cancer indication, ongoing chemotherapy treatments and nutritional supplements, age, gender, weight, height, lifestyle and genetics for personalization of nutrition.
Use of nutritional supplements – vitamins, herbs, minerals, probiotics, and other specialty categories are increasing. Supplements are high concentrations of active ingredients which are also found in different foods. Difference between supplements and foods being that foods contain more than one active ingredient at much lower concentrations. Every active ingredient in an extract or nutritional supplement or food has a unique mechanism of action which can influence nutrition decisions.
These are some example questions which nutrition planning should help answer for you. Should you take supplements Feverfew? Should you take it when at genetic risk of cancer for mutation of gene FLT3? Should you take it when at genetic risk of cancer for mutation of gene POLH? Should you take it when diagnosed with Primary Mucinous Stomach Adenocarcinoma? Should you take it when diagnosed with Primary Monoclonal gammopathy of undetermined significance? Should you take it when on Lenalidomide treatment? Should you continue taking it if you change your treatment from Lenalidomide to Pembrolizumab? So a general explanation like – it is organic and plant-based or it increases immunity is not sufficient information for making a decision of use of Feverfew extracts and nutritional supplements.
Genetic variations across cancer patients can be different and hence no two cancers are alike. The improved availability of “personalized to genetics” chemotherapy treatments and cancer disease monitoring via blood and saliva have been significant factors to improve outcomes. The earlier the lifestyle and treatment intervention – the better the influence on outcome. Genetic testing has the potential to assess cancer risk and susceptibility early. But for at-risk individuals besides regular monitoring in most cases there are no therapeutic treatment intervention options available. After diagnosis with cancer such as Primary Monoclonal gammopathy of undetermined significance or Primary Mucinous Stomach Adenocarcinoma, the treatments get personalized to tumor genomics and factors like staging of disease, age and gender. During cancer remission (after treatment cycle is complete) – monitoring is used for assessment of any relapse and accordingly decide on next steps. A large majority of cancer patients and those at-risk may take nutritional supplements like Feverfew.
So the question is that are all genetic risks and cancer indications to be considered uniformly when making decisions on the use of Feverfew extracts or nutritional supplements? Are the biochemical pathway implications of genetic risk for cancer due to mutation of gene FLT3 the same as due to mutation of gene POLH? Are the implications of Primary Monoclonal gammopathy of undetermined significance the same as Primary Mucinous Stomach Adenocarcinoma? Is it one and the same if you are on treatment with Pembrolizumab or Lenalidomide?
Feverfew – An Extract or Nutritional Supplement
Feverfew is a flowering plant native to Eastern Europe and Asia Minor. The name comes from the Latin word “febrifugia”, which means “fever reducer”. The dried leaves and shoots (the aerial parts of the plant) are used for medicinal purposes. Feverfew is considered to have anti-inflammatory benefits and has been traditionally used for various conditions :
- As a pain reliever
- For headaches
- For fever
- For coughs and colds
- For Uterine disorders
- For inflammatory conditions such as arthritis
Feverfew supplements contain many active ingredients including Luteolin, Vitamin K, Centaureidin and Parthenolide at different concentration levels. The molecular pathways which are regulated by Feverfew include Hypoxia, WNT Beta Catenin Signaling, Stem Cell Signaling and JAK-STAT Signaling. These biochemical pathways directly or indirectly regulate specific cancer molecular endpoints like growth, spread and death of cancer cells. Because of this biological regulation – for cancer nutrition, the right choice of supplements like Feverfew individually or in combination is an important decision to be made. When making decisions on the use of supplement Feverfew over other nutritional supplements – do consider all these factors.
Who Should not take Feverfew Supplements and Why?
There is no easy way to answer the question “For which cancers should I not chooseFeverfew nutritional supplements”. Just like the same chemotherapy treatment does not work across patients, for similar reasons Feverfew in comparison with other nutritional supplements may be beneficial or not. Along with which cancer and associated genetics – the ongoing treatments, lifestyle habits, height, weight and food allergies are all factors in deciding if Feverfew should be avoided or not and why.
1. Will Feverfew Supplements benefit Primary Mucinous Stomach Adenocarcinoma patients undergoing Pembrolizumab treatment?
Primary Mucinous Stomach Adenocarcinoma is characterized and driven by specific genetic mutations like GRIN3A, TMEM26 and TP53 leading to biochemical pathway changes in WNT Beta Catenin Signaling, Cell Cycle Checkpoints and Apoptosis. A cancer treatment like Pembrolizumab works through a specific pathway mechanism of action. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach which is effective. In such a condition any food or nutritional supplement which has a contrary effect to the treatment or reduces the overlap should be avoided. As an example, Feverfew supplement should not be taken for Primary Mucinous Stomach Adenocarcinoma along with treatment Pembrolizumab. Feverfew supplement impacts the biochemical pathway called WNT Beta Catenin Signaling which either promotes drivers of the disease and/or nullifies the treatment effect. Some of the factors which should be considered when choosing nutrition are type of cancer, treatments and supplements being taken currently (if any
2. Will Feverfew Supplements benefit Primary Monoclonal gammopathy of undetermined significance Patients undergoing Lenalidomide Treatment?
Primary Monoclonal gammopathy of undetermined significance is characterized and driven by specific genetic mutations like LATS2, ZMYM2 and CDK8 leading to biochemical pathway changes in Hypoxia and Hippo Signaling. A cancer treatment like Lenalidomide works through specific pathway mechanisms. The goal is to have a good overlap between the treatment and cancer driving pathways for a personalized approach. In such a condition any food or nutritional supplement which supports treatment action or improves the overlap should be considered. As an example, Feverfew supplements should be considered for Primary Monoclonal gammopathy of undetermined significance along with the treatment Lenalidomide. Feverfew supplement impacts pathways/processes like Hypoxia which either obstruct drivers of Primary Monoclonal gammopathy of undetermined significance and/or improve Lenalidomide treatment effect.
Foods to Eat After Cancer Diagnosis!
No two cancers are the same. Go beyond the common nutrition guidelines for everyone and make personalized decisions about food and supplements with confidence.
3. What about Feverfew Supplements for Healthy Individuals with POLH Mutation associated Genetic Risk?
Different companies offer panels of genes to be tested for assessing genetic risk to different cancers. These panels cover genes associated with cancers of the breast, ovary, uterus, prostate, and gastrointestinal system and others. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant may also guide testing and diagnosis of at-risk relatives. POLH is one of the genes generally available in panels for cancer risk testing.
POLH mutation causes biochemical pathways/processes like Stem Cell Signaling and DNA Repair to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Feverfew should not be taken when the genetic panel identifies mutation of POLH for Skin Cancer. Feverfew impacts pathways/processes like Stem Cell Signaling and creates adverse conditions with POLH.
4. What about Feverfew Supplements for Healthy Individuals with FLT3 Mutation associated Genetic Risk?
FLT3 is one of the genes available in panels for cancer risk testing. FLT3 mutation causes biochemical pathways/processes like JAK-STAT Signaling, MAPK Signaling and PI3K-AKT-MTOR Signaling to get impacted. These pathways are direct or indirect drivers of cancer molecular endpoints. Feverfew supplements may be considered when the genetic panel identifies mutations in FLT3 for Acute Myeloid Leukemia. Feverfew impacts pathways/processes like JAK-STAT Signaling and creates a canceling effect in those individuals with FLT3 mutation.
* Other Factors are also included like BMI, Treatments, Lifestyle Habits
It is important to remember that cancer chemotherapy treatments and nutrition are never the same for everyone. Food and nutritional supplements like Feverfew are chosen by you and can influence outcomes.
“What should I eat?” is a commonly asked question by cancer patients and those at-risk. The answer to this question depends on cancer indication, underlying genetics, current chemotherapy treatments, food allergies, lifestyle information, and food preferences.
The addon.life approach to nutrition personalization uses knowledge of active ingredients contained in foods and nutritional supplements, cancer biology, chemotherapy treatment action and genetic mutation prevalence across cancer indications. addon.life team of clinicians, clinical scientists and engineers are experts in cancer biology focusing only on nutrition personalization for cancer patients and those at-risk.
What food you eat and which supplements you take is a decision you make. Your decision should include consideration of the cancer gene mutations, which cancer, ongoing treatments and supplements, any allergies, lifestyle information, weight, height and habits.
The nutrition planning for cancer from addon is not based on internet searches. It automates the decision making for you based on molecular science implemented by our scientists and software engineers. Irrespective of whether you care to understand the underlying biochemical molecular pathways or not - for nutrition planning for cancer that understanding is needed.
Get started NOW with your nutrition planning by answering questions on the name of cancer, genetic mutations, ongoing treatments and supplements, any allergies, habits, lifestyle, age group and gender.
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
- Flavonoids as receptor tyrosine kinase FLT3 inhibitors.
- cBioPortal for Cancer Genomics
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
- HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
- Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin.
Personalized Nutrition for Cancer!
Cancer changes with time. Customize and modify your nutrition based on cancer indication, treatments, lifestyle, food preferences, allergies and other factors.